Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

Gosney, J.R. (J. R.); Paz-Ares, L. (Luis); Jänne, P. (P.); Kerr, K.M. (K. M.); Leighl, N.B. (Natasha B.); Lozano, M.D. (María Dolores); Malapelle, U. (Umberto); Mok, T.S. (Tony S.); Sheffield, B.S. (B. S.); Tufmah, A. (A.); Wistuba, I.I. (Ignacio I.); Peters, S. (S.)

Palabras clave :

Reflex testing
Molecular pathology
Turnaround time
Predictive biomarkers
NSCLC
Non-small-cell lung cancer

Fecha de publicación :

2023

Versión del Editor:

https://pubmed.ncbi.nlm.nih.gov/37356358/

ISSN :

2059-7029

Nota:

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Cita:

Gosney, J. R.; Paz-Ares, L.; Jaenne, P.; et al. "Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation". Esmo open. 8 (4), 2023, 101587

Resumen

Biomarker tests in lung cancer have been traditionally ordered by the treating oncologist upon confirmation of an appropriate pathological diagnosis. The delay this introduces prolongs yet further what is already a complex, multi-stage, pre-treatment pathway and delays the start of first-line systemic treatment, which is crucially informed by the results of such analysis. Reflex testing, in which the responsibility for testing for an agreed range of biomarkers lies with the pathologist, has been shown to standardise and expedite the process. Twelve experts discussed the rationale and considerations for implementing reflex testing as standard clinical practice.

URI :

https://hdl.handle.net/10171/67601

DOI:

10.1016/j.esmoop.2023.101587

Aparece en las colecciones:

DA - CUN - Patología mamaria - Artículos de revista

Ficheros en este ítem: